1 2 3 4 5 6 7

VII - CONCLUSIONS AND PERSPECTIVES

Better knowledge of the natural history of DLGG (growth, infiltration and inevitable degeneration) associated with a risk minimization of each treatment has transformed the ’classic’ abstentionist attitude into a resolutely therapeutic attitude.

The goal from now on is towards the development of dynamic and tailored strategy for each patient, namely to determine the sequence and timing of each treatment (single to multiple safe maximal surgical resections within cortical-to-sub-cortical functional borders or single to multiple chemotherapy and radiotherapy sessions) depending on the tumor progression (measured on regular follow up MRI scan), and the clinical and neuropsychological condition and functional brain anatomy of the individual (studied by brain mapping methods and capable of reorganizing through the mechanisms of neuroplasticity) so as to prevent malignant transformation as long as possible while preserving the quality of life.

Only a multidisciplinary approach to multi-center networks can afford to give a real future to patients with this chronic brain disease, with the possibility to design long-term projects be them socio-professional as well as at household level- especially those with plans to become pregnant. The next step would be that of early screening in order to provide preventive treatment(49)..

VIII - BIBLIOGRAPHIE

1. Aaronson NK, Taphoorn MJ, Heimans JJ, et al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 2011;29:4430–5.B2
2. Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients. Acta Neurochir 2009;151:1359-1365.B2
3. Benzagmout M, Gatignol P, Duffau H. Resection of World Health Organization grade II gliomas involving Broca’s area: methodological and functional considerations. Neurosurgery 2007;61:741-752.C4
4. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784–1791.C3
5. Blonski M, Taillandier L, Herbet G, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012;106:353-366.C3
6. Brown R, Zlatescu M, Sijben A, et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008;14:2357–2362.C4
7. Caiseras GB, Chleang S, Babb J et al. Relative cerebral blood volume measurements of Low Grade Gliomas predict patients outcome in a multi-institution setting. Eur J. Radiol 2010;73:215-220.C4
8. Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric WHO grade II gliomas: a series of 1097 cases. J Neurosurg 2013;118:1157-1168.B2
9. Chaichana KL, McGirt MJ, Laterra J, et al. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 2010;112,10-17.C4
10. Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 2008;109:817–824.B2
11. Chang EF, Clark A, Smith JS, et al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long term survival. J Neurosurg 2011;114, 566-573.C3
12. Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 2008;247: 170–178.C4
13. Daniels TB, Brown PD, Felten SJ, et al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 2011;81:218-224.B2
14. de Benedictis A, Moritz-Gasser S, Duffau H. Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas. Neurosurgery 2010;66:1074-1084.C3
15. Dehgani F, Schachenmayr W, Laun A, Korf H. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 1998;95:493-504.C4
16. Desmurget M, Bonnetblanc F, Duffau H. Contrasting acute and slow growing lesions: a new door to brain plasticity. Brain 2007;130:898-914.NA
17. de Witt Hamer PC, Gil Robles S, Zwinderman A. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 2012;30: 2559-2565.A1
18. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009;8:810-818.A1
19. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol 2005;4:476-486.NA
20. Duffau H. Brain plasticity and tumors. Adv Tech Stand Neurosurg 2008;33:3-33.NA
21. Duffau H. Surgery of low-grade gliomas: towards a "functional neurooncology". Curr Opin Oncol 2009;21:543-549.NA
22. Duffau H. Brain Mapping: From Neural Basis of Cognition to Surgical Applications. Duffau H. (Ed.), Springer Wien New York, 2011.NA
23. Duffau H. The challenge to remove diffuse low grade gliomas while preserving brain functions. Acta Neurochir (Wien) 2012;154:569-574.NA
24. Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta Neurochir (Wien) 2012;154:575-584.C4
25. Duffau H. Cognitive assessment in glioma patients. J Neurosurg 2013;119:1348-1349.NA
26. Duffau H. Diffuse Low Grade Glioma in Adults: Natural History, Interaction with the Brain, and New Individualized Therapeutic Strategies. Duffau H. (Ed.), Springer London, 2013.NA
27. Duffau H. The huge plastic potential of adult brain and the role of connectomics: New insights provided by serial mappings in glioma surgery. Cortex, in press.NA
28. Duffau H, Capelle L. Preferential brain locations of low grade gliomas. Cancer 2004;100:2622-2626.B2
29. Duffau H, Gatignol P, Mandonnet E, Capelle L, Taillandier L. Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with grade II glioma in the dominant hemisphere. J Neurosurg 2008; 109: 461-471.C4
30. Duffau H, Lopes M, Arthuis F, et al. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 2005;76:845-851.B2
31. Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 2009;27:3712–3722.A1
32. Gerin C, Pallud J, Grammaticos B, et al. Improving the time-machine: estimating date of birth of grade II gliomas. Cell Prolif 2012;45:76-90.C4
33. Ghareeb F, Duffau H. Intractable epilepsy in paralimbic Word Health Organization Grade II gliomas: should the hippocampus be resected when not invaded by the tumor? J Neurosurg 2012;116:1126-1234.B2
34. Giussani C, Roux FE, Ojemman J, et al. Is preoperative functional magnetic resonance imaging reliable for language areas mapping in brain tumor surgery? Review of language functional magnetic resonance imaging and direct cortical stimulation correlation studies. Neurosurgery 2010;66:113-120.NA
35. Guillevin R, Menuel C, Duffau H, et al. Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol 2008;87:181–187.C4
36. Guillevin R, Menuel C, Taillibert S, et al. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. Br J Cancer 2011;104:1854-1861.C4
37. Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients. J Neurosurg 2012;117:1039-1052.C4
38. Jakola AS, Myrmel KS, Kloster R, et al: Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308:1881–1888, 2012.B2
39. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy on low-grade cerebral glioma. European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Inj J Radiat Oncol Biol Phys 1996;36:549-556.A1
40. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010;177:2708-2714.B2
41. Klein M, Duffau H, De Witt Hamer PC. Cognition and resective surgery for diffuse infiltrative glioma: an overview. J Neurooncol 2012;108:309-318.NA
42. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004; 25:746–755.C4
43. Leclercq D, Duffau H, Delmaire C, et al. Comparison of diffusion tensor imaging tractography of language tracts and intraoperative subcortical stimulations. J Neurosurg 2010;112:503-511.C4
44. Louis D, Ohgaki H, Wiestler O, Cavenee W, eds. World Health Organization Classification of Tumors of the Central Nervous System, 4 edn. Lyon: IARC, 2007.NA
45. MacGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63:700-707.C3
46. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003;53:524–528.NA
47. Mandonnet E, Capelle L, Duffau H. Extension of paralimbic low-grade gliomas: toward an anatomical classification based on white matter invasion patterns. J Neurooncol 2006;78:179-185.NA
48. Mandonnet E, Pallud J, Fontaine D, et al. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev 2010;33, 91-96.NA
49. Mandonnet E, De Witt Hamer PC, Pallud J, et al. Silent diffuse low-grade glioma: towards screening and preventive treatment? Cancer, in press.NA
50. Martino J, Taillandier L, Moritz-Gasser S, et al. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien) 2009;151:427-436.C3
51. Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 2006;60:380-383.B2
52. Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol 2009; 11:176–182.C3
53. Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol 2010;68:727-733.NA
54. Pallud J, Varlet P, Devaux B, et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology 2010;74:1724-1731.C4
55. Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological MRI follow-up of low-grade glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71:729-740.NA
56. Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro-Oncology 2013;15:595-606.B2
57. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076-2084.A1
58. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646–651.A1
59. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 2007;61:484-490.B2
60. Rigau V, Zouaoui S, Mathieu-Daudé H, et al. French Brain Tumor DataBase: 5-year histological results on 25756 cases. Brain Pathol 2011;21:633-644.B2
61. Rigau V. Histological Classification. In Diffuse Low Grade Glioma in Adults: Natural History, Interaction with the Brain, and New Individualized Therapeutic Strategies. Duffau H. (Ed.), Springer London, 2013.NA
62. Rudà R, Bello L, Duffau H, et al. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro-Oncology 2012;14:iv55-iv64.NA
63. Sanai N, Mirzadeh Z, Berger M.S. Functional outcome after language mapping for glioma resection. N Engl J Med 2008;358:18-27.C3
64. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg 2011;115:948-965.NA
65. Schomas DA, Lack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 2009;11:437-445.C4
66. Schucht P, Ghareeb F, Duffau H. Surgery for low-grade glioma infiltrating the central cerebral region: location as a predictive factor for neurological deficit, epileptological outcome, and quality of life. J Neurosurg 2013;119:318-323.C3
67. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/ Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267–2276.A1
68. Shaw EG, Wang M, Coons SW, et al. Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU and vincristine (PCV) chemotherapy for adult low grade gliomas (LGG). J Clin Oncol 2012;30:3065-3070. A1
69. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26:1338-1345.B2
70. Smits A, Baumert BG. The clinical value of PET with amino acid tracers for gliomas WHO grade II. Int J Mol Imaging. 2011;2011:372509.NA
71. Smits A, Duffau H. Seizures and the natural history of World Health Organization grade II gliomas: a review. Neurosurgery 2011;68:1326-1333.NA
72. Soffietti R, Baumert B, Bello L, et al. Guidelines on management of low grade gliomas: report of an EFNS-EANO task force. Eur J Neurol 2010;17:1124-1133.NA
73. Teixidor P, Gatignol P, Leroy M, et al. Assessment of verbal working memory before and after surgery for low-grade glioma. J Neurooncol 2007;81:305-313.C3
74. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985-990.A1
75. van den Bent M, Wefel J, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583-593.NA
76. Weller M, Berger H, Hartmann C, et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker ? Clin Cancer Res 2007;13:6933–6937.B2
77. Yordanova Y, Moritz-Gasser S, Duffau H. Awake surgery for WHO grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection. J Neurosurg 2011;115:232-239.B2

1 2 3 4 5 6 7